Compounds for binding proprotein convertase subtilisin/kexin type 9
Abstract:
The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity, for treatment of a disease or condition mediated, at least in part, by PCSK9. The compounds of the disclosure include compounds Formula (I).
Information query
Patent Agency Ranking
0/0